Search results
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 13 minutes agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 1 hour ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Merck Expands Access to High-Quality Maternal Care for More
3BL CSRwire· 1 hour agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative, has reached more than 30 million ...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks via Yahoo Finance· 4 days agoMerck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good...
Data-Based Insights About Merck & Co Inc
Stocks Register· 4 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value ...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 52 minutes agoAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during ...
Tri-Cities doctor fined after prescribing ivermectin for COVID. 2nd physician charged
Tri-City Herald via Yahoo News· 2 days agoOne doctor joined in a lawsuit against the Washington Medical Commission with the help of the Silent...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 3 days agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
3 Biotech Stocks to Double Your Money in the Next 24 Months
InvestorPlace via Yahoo Finance· 7 days agoThe biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments...
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
Digital Journal· 2 hours agoASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of ...